For the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with systemic drug products, including biologics, or when use of those therapies is inadvisable.1
Skin clearance and itch reduction were studied with and without TCS
Studied in 1623 adults with moderate-to-severe AD
** This is an optional area where footnotes can live.
CIBINQO is a once-daily oral treatment option
JAK=Janus kinase.
CIBINQO is a JAK inhibitor
JAK=Janus kinase.
A quick reference guide that outlines what you need to know about starting appropriate patients on CIBINQO
** This is an optional area where footnotes can live.
Have a product question? Request a call from your product representative
** This is an optional area where footnotes can live.
CIBINQO (abrocitinib) is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.
CIBINQO is indicated for the treatment of adults with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Limitations of Use: CIBINQO is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants.